The interactions of isoleucyl-tRNA synthetase (IleRS,E
1 is a clinically used topical antibiotic that acts via inhibition of isoleucyl-tRNA synthetase (IleRS; E). The inhibition causes depletion of cellular charged tRNA Ile levels, blocking protein synthesis and results in induction of the stringent response (1, 2). Although, compounds of this type are known to act through highly potent and selective inhibition of bacterial IleRS (3, 4) , their precise mechanism of interaction with IleRS has not been elucidated. Nonetheless, considerable efforts have been made to produce a large range of semi-synthetic analogues of PS-A that have improved properties (e.g. Refs. [5] [6] [7] [8] , for example, through replacement of the metabolically-labile C-1 ester function in PS-A (e.g. in SB 205952, Fig. 1 ). The working model for this work has been an assumption that the epoxide-containing side chain of PS-A, which has the same carbon skeleton as L-isoleucine, occupies the same enzyme binding site as the amino acid substrate. In the same way, the tetrahydropyran ring has been considered as a possible mimic for the ribose in the activated amino acid reaction intermediate, Ile-AMP. As a result, these features have been relatively invariant in PS-A analogues, although a naturally occurring derivative in which the epoxide is replaced with a carbon-carbon double bond retains high potency for IleRS (e.g. ethyl monate C).
In contrast, the other side chain of PS-A (i.e. the right-hand side of the structures shown in Fig. 1 ) has no obvious similarity to the substrates or intermediates of the IleRS reaction. This part of the PS-A molecule has therefore been the subject of most modification (e.g. Refs. [5] [6] [7] [8] . However, the consequences of modification to this portion of the molecule on the interaction of this class of compound with IleRS have not, until now, been studied in any detail.
One of the key target organisms for PS-A is Staphylococcus aureus, which is often the cause of upper respiratory tract and nasal infections, and which may be resistant to other classes of antibiotic (e.g. Ref. 1). S. aureus strains resistant to PS-A itself have been identified and the resistance mechanism, at least in some cases, shown to be attributed to mutations in IleRS (e.g. Refs. 9 -11). Our ultimate goal is to investigate how a more rational approach could be taken to inhibitor design, particularly with respect to overcoming resistance. We have characterized in detail the kinetics and mechanism of substrate binding and catalysis by S. aureus IleRS (12) and, in the present paper, inhibition by PS-A analogues. Understanding the detailed structure-activity relationships for this class of inhibitor has subsequently led to the development of even more potent compounds. 2 In addition, we wanted to develop the models for binding of PS-A analogues outlined above by relating their interaction with IleRS to those of the substrates and, more importantly, reaction intermediates. We therefore compared the properties of PS-A analogues with non-hydrolyzable derivatives of the normal activated amino acid intermediate, Ile-AMP. Aminoalkyl adenylates such as isoleucinyl adenylate (Ile-ol-AMP; Fig.  1 ) have long been recognized as potent inhibitors of aminoacyl-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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tRNA synthetases (e.g. Refs. 13 and 14) . Compounds in which the phosphate group is replaced by a sulfamate (e.g. Ile-NHSO 2 -AMP; Fig. 1 ) have more recently been used in cocrystallisation experiments with a number of aminoacyl-tRNA synthetases (e.g. Ref. 15) . The analogy of these compounds to Ile-AMP is, of course, much more obvious than that of PS-A. In this paper, we have compared the kinetics, thermodynamics, and effect upon IleRS conformation (reported by changes in tryptophan fluorescence; see Ref. 12) of the two classes of compound and related these observations to the IleRS reaction cycle and the effect of IleRS mutations known to alter PS-A sensitivity (e.g. Ref. 10) . This work was given extra impetus by the recent solution of the crystal structure of the Thermus thermophilus IleRS⅐PS-A complex (16, 17) .
MATERIALS AND METHODS
IleRS and Other Reagents-IleRS from S. aureus was purified (to Ͼ98% as judged by SDS-polyacrylamide gel electrophoresis or reverse phase HPLC) from Escherichia coli DH1 cells carrying the pDB575 plasmid (18) and shown to be fully active by active-site titration performed either through the measurement of a burst of Mg⅐ATP utilization (19) or the measurement of the stoichiometric IleRS⅐[
14 C]Ile-AMP complex by gel-filtration. Except where otherwise stated, reagents were of the highest grade available and purchased mainly from Sigma (Poole, Dorset, United Kingdom).
Inhibitors-PS-A and ethyl monate-A (Et-A) were isolated from producing Pseudomonas fluorescens strains as described by Fuller et al. (20) . SB-205952 was prepared as described by Broom et al. (8) . Fermentatively produced 3 H-labeled PS-A was a kind gift from Dr. Brian Ford (SmithKline Beecham) and was prepared as described by Cassobianco et al. (21) .
IleRS and Steady-state Enzyme Kinetics-tRNA aminoacylation and PP i /ATP exchange assays were performed using modifications to previously described methods (22) . All assays were performed at 22°C in 50 mM Tris-HCl, pH 7.9, 10 mM MgCl 2 , 50 mM KCl, and 2 mM dithiothreitol (buffer A). Aminoacylation assays (200 l) were performed using 0.2-5 nM IleRS, L-[U- 14 C]isoleucine (Amersham; specific activity ϭ 11.5 MBq/ mmol) and 4 mg/ml (final concentration) E. coli MRE 600 tRNA (Boehringer Mannheim; equivalent to ϳ4 M tRNA Ile ). After specific intervals, 50-l aliquots (ϫ 3) were quenched using 100 l of 7% trichloroacetic acid and incubated on ice for 10 min. Trichloroacetic acid-precipitable material was harvested using Millipore Multiscreen 0.45-m polyvinylidene difluoride 96-well plates (Millipore, Watford, Herts, UK) and counted by liquid scintillation.
Steady-state PP i /ATP exchange was monitored using 1 nM IleRS, 2 mM 32 P-labeled sodium. PP i (specific activity about 3 TBq/mmol) and 2 mM ATP and 2 mM L-isoleucine in buffer A. All reactants (IleRS, PP i , ATP etc.) were preincubated for 2 h at 37°C prior to initiation of 32 P-labeled isotopic exchange by the addition of a small amount of [ 32 P]PP i , perturbing the total chemical concentration of PP i by less than 1%. Reactions were allowed to proceed for 10 min, quenched, and counted as described above. Reactions were quenched after 10 min using 0.2 M pyrophosphate in 7% perchloric acid. The reaction mixture was harvested by adsorption onto activated charcoal (Sigma, Poole, UK) which was subsequently collected on Millipore Multiscreen 0.45-m polyvinylidene difluoride 96-well plates. Following desorption of [ 32 P]ATP from the charcoal using ethanolic ammonia, the incorporation of 32 P into ATP was determined by liquid scintillation counting. In all experiments shown, reaction rates were shown to be linear with respect to protein concentration and time (Ͻ50% tRNA acylation).
[ 3 H]PS-A Exchange Measurements-Reversal rate constants for inhibitor complexes were measured by pre-forming the inhibitor complex with the desired inhibitor, isolation by rapid gel filtration (Pharmacia Fast desalt column), followed by addition of a large excess of 3 H-labeled PS-A (10 M; 1.2 TBq/mmol). After predetermined incubation times at 22°C, samples were removed and 3 H-labeled enzyme isolated by gel filtration, followed by scintillation counting.
Stopped-flow/Steady-state Fluorescence Measurements-A Model SX17MV stopped-flow spectrophotomer (Applied Photophysics Ltd., Leatherhead, UK) fitted with a 150 W Xe arc lamp was used for all stopped-flow experiments with excitation at 290 -295 nm (2 mm excitation slits). Fluorescence emission from enzyme Trp residues was observed through a Corion 300-nm cut on filter. All reactions were performed at 22°C in buffer A. The reported concentrations of reactants are those in the reaction chamber subsequent to mixing. Typically, each trace shown is the average of at least four individual experiments, and the observed rate constants reported represent the mean and standard deviation of that data set. Measurements of steady-state (or time course greater than 2 min) IleRS fluorescence were performed using an SLM Aminco Bowman Series 2 Spectrometer using excitation wavelengths of 290 and emission at 350 nm (2-10 nm slit widths).
Kinetic Data Analysis-Stopped-flow kinetic time courses were analyzed using the non-linear least-squares fitting routines supplied by Applied Photophysics. All other least squares fitting was performed using GRAFIT (23) . Kinetic simulation was performed using the MS-DOS version of KINSIM (24) or the Windows NT version of GESPASI (25, 26) .
RESULTS
Inhibitors of IleRS-In this study, examples from two structural classes of potent IleRS inhibitor were characterized (Fig.  1) . The properties of PS-A analogues were studied by comparing this compound to one natural (Et-A) and one semi-synthetic analogue (SB-205952). The latter compound was of particular interest as it has been shown to have an extended spectrum of antibacterial action (8, 27) , and possessed a nitrofuryl chromophore that had the potential to undergo energy transfer interactions with IleRS tryptophan residues upon binding. We compared these PS-A derivatives with two non-hydrolyzable analogues of Ile-AMP, Ile-ol-AMP and Ile-NHSO 2 -AMP ( IleRS activity was time-dependent, resulting in curvature of enzyme progress curves. An example of a typical such experiment, examining the effect of varying concentrations of the nitrofuryl oxazole monic acid analogue, SB-205952, on IleRS tRNA aminoacylation activity (initiated by adding enzyme) is shown in Fig. 2A .
This type of time-dependent inhibition may originate from a number of mechanisms, including enzyme modifying agents (e.g. Ref. 28 ), however, independent experiments confirmed that the inhibition by this class of compounds was reversible (see also below). It therefore seemed likely that PS-A analogues inhibit IleRS via a slow-binding competitive mechanism that is most commonly described by Scheme 1 (29, 30) .
This model (Scheme 1) assumes that inhibition can be described by a discrete two-step process in which the initial E⅐J complex undergoes a relatively slow isomerization to form a tightened E * ⅐J complex (29) . 3 Working on this assumption, we fitted individual tRNA aminoacylation progress curves obtained in the presence of inhibitor (e.g. Fig. 2A ) to Equation 1 (30) ,
where v o and v s represent initial and steady-state velocities of IleRS aminoacylation and k obs is the apparent rate constant for the progression of E⅐J to E * ⅐J at any particular inhibitor concentration. Methods to determine the relevant kinetic parameters for this type of mechanism directly from enzyme progress curves have been described (e.g. Ref. 30) . However, such experiments have invariably been performed using continuous spectrophotometric assays which allow considerable precision in determining enzyme progress kinetics. In particular, these methods depend upon the accurate measurement of both k obs and the final steady-state inhibited rates (i.e. at overall equilibrium for formation of E * ⅐J). Existing assays for both aminoacylation and the partial PP i /ATP exchange reaction routinely only allow single time point sampling which limits their utility in this type of approach. In addition, both assays have a rather limited dynamic range in relation to their inherent signal/noise (determined by the radiolabeled amino acid specific activity and tRNA concentration). We made considerable efforts to improve these assays (e.g. Refs. 31 and 32), but the data shown in Fig. 2A probably represents close to the maximum level of precision available.
From Scheme 1 (assuming k Ϫj Ͼ Ͼ k ϩj * ; i.e. equilibrium for formation of E⅐J is rapid compared with subsequent steps), the effect of increasing inhibitor concentrations on k obs should be described by Equation 2,
and so would therefore be predicted to be hyperbolic, with intercept and asymptote values of k Ϫj * and (k Ϫj * ϩ k ϩj * ), respectively. However, the time and signal amplitude resolution of manual sampling assays for IleRS aminoacylation activity was such that the limiting value of k obs could not be approached (e.g. see Fig. 2B ). As a result, for all monic acid analogues that we have tested, plots of k obs versus [I] are linear within the operating limits of the assays and therefore yield only a very approximate estimate of k Ϫj * (e.g. Fig. 2B ) and a pseudo secondorder rate constant (k on ) for progression of E⅐J to E * J (when k obs Ͻ Ͻ k ϩj * ), described by Equation 3,
where
The mean (Ϯ S.E.; n ϭ 3) values for k on for SB 205952 and PS-A measured in time course experiments similar to that shown in Fig. 2A were, SB 205952,
The value of k Ϫj * (Scheme 1) dictates the kinetic stability of the tightened E*⅐J complex but experiments such as those shown in Fig. 2 could only yield approximations to this parameter. In many cases (e.g. PS-A), the intercept in plots such as those shown in Fig. 2B were not significantly different to zero. However, secondary plots for SB 205952 yielded an estimate for the intercept consistently greater than zero (8 Ϯ 3 ϫ 10 Ϫ4 s Ϫ1 ; n ϭ 3). These data therefore suggested that the E*⅐J complex was appreciably less kinetically stable with SB 205952 (t 1/2,off predicted to be around 15 min) than with PS-A (see below).
The slope of k obs versus (J) secondary plots, k on , was used to predict reaction conditions in which there was Ͻ50% progres- 3 Simple competitive inhibitors are typically referred to in the text as I and time dependent/slow binding inhibitors as J. K j * refers to the apparent overall equilibrium dissociation constant for J, K j the initial binding step, and K* the subsequent isomerization equilibrium constant for the tightening step (in the forward direction). sion from E⅐J to E*⅐J, thus making a negligible contribution to the analysis. The validity of the above assumptions is demonstrated by our ability to calculate reasonable estimate of k j * of 200 pM using the foregoing data (cf. 50 pM, Table I ). Under these conditions, PS-A analogues behave as simple linear competitive inhibitors and could therefore be described by Equation 5, Fits to other models of inhibition (e.g. non-competitive, uncompetitive, mixed) either did not converge, or were statistically less valid. Similar experiments with Ile-ol-AMP and Ile-NHSO 2 -AMP showed that binding of these compounds was also competitive but, as inhibition was not time-dependent, experiments could be conducted using longer time courses (e.g. 5-10 min; see also Ref. 12) . The data for these compounds are summarized in Table I . Therefore, under initial binding conditions all of the compounds characterized in this paper appeared as simple competitive inhibitors with either of the activating substrates ATP and Ile. Virtually identical data were obtained by examining the effect of these compounds on initial PP i /ATP exchange (data not shown).
As all of the inhibitors (PS-A and Ile-AMP analogues) were competitive with respect to both of the activating substrates, the effects of both ATP and isoleucine concentration upon the measurement of K i,app (K j,app in the case of PS-A analogues) must be taken into account. Moreover, characterization of the IleRS reaction cycle (12) showed that binding of Ile and ATP is thermodynamically linked, making this factor more important. Rather than seeking an analytical solution to this problem, we approached it through numeric simulation techniques, using the reaction state model that we had developed for binding and activation of substrates by IleRS (12) . Simulations of steadystate inhibition predicted that compounds which competed with both Ile and ATP would yield linear competitive inhibition kinetics (i.e. fit to Equation 5) when one substrate was fixed and the other varied. Under the conditions of the experiment shown in Fig. 3 , values of K i,app (or K j,app ) were shown to be linearly related to the true K i (or K j ), but were a 3.2-fold overestimate (see also Ref. 12) .
Tight-binding Effects Dominate the Inhibition Kinetics at Steady-state-All of the experiments described in this paper were performed using pure S. aureus IleRS that was shown to be completely functional using active-site titrations (see "Materials and Methods"). Despite this, the catalytic activity of IleRS (coupled with the specific activity of commercially available radioisotopically-labeled substrates) set a lower limit on the IleRS concentration that could be used in assays of around 1 nM both for measurement of tRNA aminoacylation and PP i / ATP exchange. For most PS-A analogues, the overall apparent dissociation constant for formation of E*⅐J (K j,app * ) was close to or below this IleRS concentration. Thus, if inhibition was allowed to progress to steady-state, the compounds showed tightbinding properties (29) .
This type of behavior is illustrated by the data shown in Fig.  4 , which shows the effect of [IleRS] on measurements of appar- 
. All data represent means of two or more independent experiments and are reported Ϯ S.E. or range.
Inhibitor class IC 50 ent inhibition obtained after 2 h preincubation of IleRS with PS-A. Under these conditions, conventional inhibition assays merely titrated the IleRS concentration, and could therefore only discriminate relatively poor inhibitors (i.e. K j,app * Ն 1 nM). This presented a major problem for obtaining appropriate comparisons between the affinity of compounds when screening large numbers of semi-synthetic monic acid analogues. For example, IleRS inhibition by SB-205952 and PS-A were virtually indistinguishable at steady-state, even though we were subsequently able to demonstrate that the true K j * value for these compounds differed by at least 20-fold (see below). One empirical approach was to determine the apparent inhibition potency following a defined preincubation (e.g. 15 min, [Ile] ϭ 2.K m,Ile ). Under these conditions, the relative potency of the PS-A analogues was PS-A Ͼ Et-A Ͼ SB-205952 (Table I) ) is a function of the specific activity of the radiolabeled amino acid substrate. Thus, increasing the concentration of amino acid results in a reduction of the product signal (unless impractically large amounts of radiolabeled amino acid are used). However, the PP i /ATP exchange partial reaction provided a convenient way of working both under true steady-state conditions and in the presence of supersaturating substrate concentrations. Fig. 5A shows time courses for [ 32 P]PP i /ATP exchange by IleRS using the same final concentrations of substrates and specific activity of [ 32 P]PP i . In one experiment, PP i /ATP exchange was initiated by the addition of IleRS and in the other, isotopic exchange was initiated by the addition of a small "spike" of [ 32 P]PP i , achieved without significantly perturbing the overall chemical concentration of PP i and performed a considerable period (2 h in this case) after all of the chemical reactants were mixed. Under these conditions, the time course of isotopic PP i /ATP exchange was almost identical in both experiments (Fig. 5A ). This approach allowed us to measure PP i /ATP exchange in an E⅐substrate⅐inhibitor mixture that had reached a true steady-state. This was shown in trial experiments in which the preincubation period prior to initiation of radioisotopic exchange was varied between 30 min and 8 h and in which the IC 50 for inhibition by compounds was unchanged after 1 h (data not shown).
Under final standard experimental conditions (2 h preincubation at 37°C), this approach successfully raised K j,app * such that it was well above [E] and therefore yielded IC 50 values directly related to K j * . Using this approach, the potency of monate analogues, which were indistinguishable by conven- Table I ). The values obtained from steady-state PP i /ATP exchange under supersaturating conditions were used to estimate the true overall K j * using the same numerical simulation approach that was applied to initial binding. These experiments confirmed that this method was reporting a true steady-state equilibrium for formation of E*⅐J. Moreover, the IC 50 values obtained were directly related to K j * (IC 50 ϭ 2300 ϫ K j * ; Table I ). Reversibility of Inhibition-The analysis of the kinetics of progression from E⅐J to E*⅐J in IleRS progress curves (e.g. Fig.  1 ) and K j * (see above) suggested that marked differences might exist in the stability of E*⅐J complexes (i.e. PS-A, cf. SB-205952). Initial experiments suggested that the E*⅐J complex formed between IleRS and SB-205952 was far less stable than that formed PS-A, as enzyme activity was completely restored after isolation of E*⅐SB-205952 by rapid gel-filtration and dialysis against high concentrations of Ile and ATP for 2 h, whereas no detectable reactivation was observed over several days when this experiments was conducted with E*⅐PS-A (data not shown). However, it is important to note that the tightbinding effects might also cause major distortions in the results of Hughes and Mellows (Ref. 4 ; e.g. gel-filtration isolation of E*⅐J, where [E] Ն K j * ). Nonetheless, as a starting point, experiments were performed to confirm the stability of the E*⅐J complex using 3 Hlabeled PS-A. Following preincubation, the E⅐[ 3 H]PS-A complex was readily isolated by gel-filtration (Fig. 6 ) and was completely intact after dialysis for greater than 2 weeks in the presence of high concentrations of isoleucine (2 mM) and frequent buffer changes (Fig. 6A, lower panel) . However, the noncovalent nature of [ 3 H]PS-A binding to IleRS was readily demonstrated by the fact that all of the 3 H counts associated with E*⅐PS-A were released at an identical elution position to native [ 3 H]PS-A when the protein was unfolded in a reverse-phase HPLC separation (Fig. 6B) . These experiments yielded a value of 1.02 Ϯ 0.03 mol/mol (mean Ϯ S.E.; n ϭ 4) for the stoichiometry of inhibitor binding to the IleRS monomer. Similar experiments were conducted with SB-205952 by estimating the area of the compound reverse phase absorbance peak directly (i.e. utilizing its yellow nitrofuryl chromophore; max ϭ 405 nm), yielding a value also close to unity. PS-A analogues therefore form a tightened reversible complex at 1:1 stoichiometry with IleRS.
To measure the kinetics of E*⅐J reversibility, [ 3 H]PS-A chase exchange experiments were performed. The kinetic mechanism underlying this approach is illustrated in Scheme 2. For two competing slow-binding ligands, when E*⅐J is isolated (i.e. free [J] ϭ 0) and mixed with a large excess of a second inhibitor . Using a rapid gel-filtration method, the labeled IleRS protein peak could be recovered with essentially baseline separation from free [ 3 H]PS-A within 2-3 min and with a reproducibility of better than 5% (data not shown). Fig. 7A shows the distribution of radioactive counts in repeat chromatograms from an experiment in which the time course of exchange of unlabeled PS-A (K) into E-labeled with [ 3 H]PS-A (J) was measured. As PS-A was the only inhibitor available in radiolabeled form, routine experiments examined the rate of 3 H exchange in the opposite direction to that shown in Fig. 7A Fig. 7B . In all cases, time courses fitted well to a single exponential function, therefore allowing k Ϫj * to be determined with reasonable precision. Similar experiments utilizing either radiolabeled inhibitor exchange or recovery of catalytic activity following gel filtration showed complete reversal of IleRS inhibition by Ile-ol-AMP within the time taken to the first measurement (typically 2-5 min; date not shown), therefore confirming that this compound inhibits IleRS by a rapid reversible competitive mechanism.
Direct Measurement of Inhibitor Binding; Effects on Enzyme Tryptophan Fluorescence-In an accompanying article (12), we describe a detailed analysis of the kinetics of substrate binding and activation by IleRS using stopped-flow techniques. This was made possible, in large part, by changes in enzyme tryptophan fluorescence that occur during binding and activation of substrates. We therefore also examined the effects of inhibitor binding upon IleRS fluorescence. The effect of binding of a range of inhibitors on steady-state IleRS fluorescence is shown in Fig. 8A . The formation of the activated amino acid analogue, Ile-AMP, during the reaction cycle results in an increase in IleRS tryptophan fluorescence of around 17% ( Fig. 8A ; see Ref.
12 for details). Satisfyingly, Ile-ol-AMP and Ile-NHSO 2 -AMP binding induced an almost identical increase in IleRS fluorescence ( Fig. 8 and Table I ). The fluorescence of the complex of IleRS with PS-A or Et-A was much more similar to that of IleRS alone; binding resulting in only around a 2% increase (Fig. 8A) . In contrast, binding of SB-205952 leads to a very large decrease in IleRS fluorescence (Fig. 8A) , which occurs presumably because of fluorescence resonance energy transfer (33) between the nitrofuryl chromophore of SB-205952 and enzyme tryptophan emission as a result of the overlap between their respective emission and absorption spectra (Fig. 8B) . Regardless of their spectroscopic origin, these changes provided a means to characterize the kinetics of inhibitor binding directly using stopped-flow techniques. Fig. 9A shows traces obtained in typical experiments in which E (0.2 M) was rapidly mixed into a large excess (25 M) of a range of inhibitors under pseudo first-order conditions. In all cases, a transient fluorescence change was observed that was best fitted to a single exponential function, defining the observed rate constant, k obs (Fig. 9) . Moreover, the amplitude of these signal changes was exactly as expected from steady-state measurements (compare Figs. 8 and 9 ). The transients observed were relatively rapid (up to Ͼ200 s Ϫ1 ), too fast to be associated with the slow isomeric transition between E⅐J and E*⅐J, so this seemed likely to be associated with the initial formation of the E⅐J binary complex.
This was confirmed when the concentration dependence of the observed rate constants, k obs , were measured as a function of inhibitor concentration (Fig. 9B) . In each case, the binding kinetics were as expected for a simple biomolecular reaction; (Fig. 9B) , showing no sign of saturation up to 100 M (data not shown) and therefore defining the apparent association rate constant (k ϩj or k ϩi ) from Equation 7 , where [J] is the inhibitor concentration,
The dissociation rate constant, k Ϫj (or k Ϫi for Ile-AMP analogues), was always too low to be determined accurately from enzyme:inhibitor mixing experiments such as that shown in Fig. 9 . Assuming k Ϫj Ϸ 0.5 s Ϫ1 these data set a upper limit for the K j (or K i ) for inhibitor binding of ϳ50 -300 nM. However, accurate values for k ϩj , together with K j values obtained from enzyme inhibition experiments (e.g. Fig. 2 ) allowed reasonable estimates to be made for k Ϫj (since K j ϭ k Ϫj /k ϩj ; Table I ).
Since IleRS inhibition experiments had shown a slow-binding inhibition mechanism for PS-A analogues, we attempted to identify further transient changes in IleRS fluorescence associated with the isomeric E⅐J 7 E*⅐J transition. We were completely unsuccessful in identifying transients of the expected time course against the background of enzyme photobleaching. The IleRS fluorescence signals obtained for binding PS-A and Et-A (e.g. Fig. 9A ) were too small to measure reproducibly, so we employed a kinetic competition approach to characterize the binding of these compounds (36) . An example of this type of experiment, in which IleRS was rapidly mixed with two-competing ligands, Ile-ol-AMP and PS-A, is shown in Fig. 10 .
Using the notation used in Scheme 2, experiments such as these in which K signifies the inhibitor which produces a signal upon binding (e.g. SB-205952), and J the spectroscopically silent inhibitor (e.g. PS-A) and k Ϫk and k Ϫj are small compared with k ϩk ⅐[K] and k Ϫj ⅐[J], then k obs and ⌬F obs vary with [K] according to ,
This therefore predicts that, for a fixed for Et-A. These data were virtually indistinguishable from estimates determined in highly averaged direct binding experiments (e.g. Fig. 9 and Table I) .
Fluorescence Measurements of Reversal of Inhibitor Binding-The finding that inhibitor complexes could be distinguished and characterized through their effects on tryptophan fluorescence presented an opportunity to measure the reversal kinetics for compounds (i.e. k Ϫj * ) without the use of radiolabeled inhibitor (cf. the approaches described above). These experiments were performed simply by observing the relaxation kinetics between E⅐inhibitor forms which differed significantly in their relative fluorescence intensity (e.g. Fig. 8 ). The principle behind the experiments was, once again, competition between two inhibitors (Scheme 2). Typically, a stoichiometric E*⅐J complex was prepared by prolonged incubation of E with inhibitor [J] under conditions in which [E] was ϾK j * . This was then mixed into a large excess of a second inhibitor [K] under conditions in which formation of E⅐K complexes was fast as described earlier. Under these conditions, all of the E⅐J (or E*⅐J) complex is converted to E⅐K but, since k ϩk ⅐[K] is Ͼ Ͼk Ϫj * , the enzyme fluorescence time course follows an exponential that defines k Ϫj * (in the case of a two-step mechanism, k Ϫi for a single-step mechanism, e.g. in the case of Ile-ol-AMP or Ile-NHSO 2 -AMP).
In experiments of this type, the relaxation rate constants were sufficiently slow that they could be readily measured using a conventional fluorimeter. Typical time courses from a number of measurements of this type are shown in Fig. 11 . In all cases, the fluorescence relaxation transient was of the expected size and clearly distinguished from background enzyme photobleaching (Fig. 11, B and C) . All of the transients fitted well to a single exponential function, as expected. In control experiments, varying the concentration of the second "chase" inhibitor had no effect on the observed rates, confirming that k ϩk [K] was Ͼ Ͼk Ϫi or k Ϫj * (dependent upon the inhibitor class; data not shown). Fig. 11C shows the measurement of essentially identical reverse rates when E⅐SB-205952 was chased with either Ile-NHSO 2 -AMP or PS-A (k Ϫj * ϭ 9.2 ϫ 10 Ϫ4 s
Ϫ1
, cf.
ϫ 10
Ϫ4 s Ϫ1 ). The data obtained using this method was in reasonable agreement with estimates from [ 3 H]PS-A exchange experiments (Table I) , but it was far less time consuming and yielded more precise data. As would be expected, reverse rates estimated for Ile-AMP analogues were much faster than those for PS-A analogues (Fig. 11) . The reversal rate constant, k Ϫi , for the E⅐Ile-ol-AMP complex was around 20-fold faster than that for E⅐Ile-NHSO 2 -AMP (k Ϫi ϭ 0.07 s Ϫ1 , cf. 5 ϫ 10 Ϫ3 s
Ϫ1
). Together, these data represent a near complete solution to the kinetics of inhibition of IleRS by the five inhibitors from two separate structural classes described in this paper. The kinetic and equilibrium parameters for all five compounds are summarized in Table I . DISCUSSION The work described in this paper has revealed, for the first time, the details of the mechanism and kinetics of inhibition of IleRS by PS-A and Ile-AMP analogues. The fact that PS-A exerts its anti-bacterial action via potent inhibition of IleRS has, of course, been known for a number of years (e.g. Refs. 1, 3, and 4). However, the extreme potency and slow-binding mechanism of this class of compounds meant that experiments to characterize their properties had to be carefully designed in order to avoid distortions in the data, for example, using assay conditions that were non-steady-state or prone to tight-binding artifacts. Such factors have hindered the determination of true structure-activity relationships using simple screening assays for this class of compound previously. For example, SB-205952 previously appeared to have very similar potency to PS-A, but this inhibitor was subsequently shown to have around 20-fold lower overall affinity for IleRS. Partly for these reasons, the major factor used to judge the utility of PS-A analogues in previous studies (e.g. Refs. 5-8) has been their anti-bacterial, rather than enzyme inhibition, properties. The development of the steady-state PP i /ATP exchange assay described in this paper overcame many of these problems by allowing the direct estimation of K j * in simple screening assays. Part of the impetus for the present work was a desire to take a more rational approach to the development of new IleRS inhibitors by relating, where possible, the mechanism and kinetics of inhibitor binding to that of substrate binding and activation during the normal catalytic cycle. We therefore also characterized the kinetics of substrate binding and activation in some detail. This work is reported in an accompanying paper (12) and the results summarized in the scheme given in Table  I . The purpose of this was 3-fold. First, we wished to characterize binding of PS-A binding further in order to better understand how the properties of this compound could account for its anti-bacterial effects (in contrast to, for example, those of Ileol-AMP and Ile-NHSO 2 -AMP which are not toxic to bacteria and show no selectivity for bacterial IleRS, cf. its mammalian counterparts). Second, we wanted to provide more data to support models for PS-A binding in relation to that of substrate/ intermediates. Such models (e.g. Refs. 4 and 37) have invariably drawn analogies between the epoxide containing side chain of PS-A and Ile and, in some cases, the tetrahydropyran ring and the Ile-AMP (or ATP) ribose. Third, we wished to use these observations to attempt to develop even more potent inhibitors and, in particular, to utilize binding interactions in IleRS that reinforce bacterial selectivity and, if possible, circumvent resistance to PS-A. The present work provides the framework upon which we based the final aim. A subsequent paper will describe the products of this effort, which has resulted in the development of IleRS inhibitors with even greater potency than those described here.
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All five inhibitors characterized in this paper possessed fairly similar initial affinities for binding to IleRS, with initial binding constant values in the range 1-100 nM and a rank order of potency as follows: Ile-NH-SO 2 -AMP Ͼ PS-A Ͼ Et-A Ͼ SB-205952 Ͼ Ile-ol-AMP. However, the Ile-AMP analogues were simple reversible competitive inhibitors that showed no evidence for allosteric tightening of inhibition. Consequently, at equilibrium (K j * K) all of the PS-A analogues have equivalent or greater potency than Ile-NHSO 2 -AMP, with estimated overall binding constants in the range 20 -400 pM. This extreme potency was reflected in the stability of the E*⅐J complex with these compounds (t 1/2,off Ն10 min). Hughes and Mellows (4) previously reported that PS-A was only removed by denaturing IleRS using urea or detergents. These observations were almost certainly the result of experiments conducted at [E] Ͼ K j * , preventing release of inhibitor. In the present paper we show, using either [ 3 H]PS-A exchange or IleRS fluorescence measurements, that binding is reversible and, using the latter method, relatively easily characterized.
Binding of inhibitors to IleRS was also characterized directly , cf. 0.004 s Ϫ1 , respectively). We have observed similar improvements in potency when comparing inhibition of other aminoacyl-tRNA synthetases by simple non-hydrolyzable reduced adenylates with their corresponding sulfamates, so this observation may be a fairly generalized one. 4 In contrast to Ile-AMP analogues, binding of PS-A or Et-A to IleRS resulted in very modest changes to IleRS fluorescence (ϳ2%). We therefore employed a kinetic competition approach to characterize binding of these compounds. The small amplitude of the change in IleRS fluorescence upon formation of E⅐PS-A or E⅐Et-A was intriguing and certainly implies a very different IleRS conformation complexed to PS-A analogues than when Ile-AMP is formed catalytically (or inhibited with Ile-AMP analogues; see above). In fact, this change in fluorescence is considerably less than that observed upon binding of Ile to E (or to the E⅐ATP binary complex (12)). However, interactions of all the inhibitors studied here with IleRS were clearly mutually exclusive with each other and with both Ile and ATP, so PS-A certainly binds in the region of the active site. No doubt, further insights into this process will be revealed when the coordinates of the recently solved crystal structure of the complex of T. thermophilus IleRS with PS-A (16, 17) become available.
In contrast to PS-A and Et-A, binding of SB-205952 to IleRS resulted in a substantial (37%) decrease in enzyme fluorescence, due to fluorescence resonance energy transfer between an inhibitor chromophore and enzyme tryptophan emission. The magnitude of this effect was much larger than might be expected given that IleRS possesses 18 tryptophan residues, spread relatively evenly thoughout its structure (18) . Based on Förster theory (33), the R o (i.e. distance for 50% energy transfer) of this fluorescence resonance energy transfer pair would be predicted to be around 20 Å which would probably cover only around one-third volume of the IleRS 106-kDa monomer. Structure based alignments of IleRS (e.g. Ref. 39 ) certainly reveal conserved tryptophan residues close to the class I aminoacyl-tRNA synthetase defining HIGH and KMSKS motifs. However, the precise contribution of individual residues is likely to only be determined by site-directed mutagenesis experiments, coupled with more sophisticated fluorescence characterization of IleRS, for example, using tryptophan lifetime analysis (e.g. Ref. 33) .
The three monate analogues studied here differed only in the nature of the right-hand chain (Fig. 1) . This component has been the predominant area upon which effort to produce PS-A analogues has been focused (e.g. Refs. [5] [6] [7] [8] . Comparisons between PS-A and Et-A or SB-205952 revealed the contribution of the PS-A side chain to each of the kinetic parameters that dictate the overall potency for binding. For example, the K j for all three compounds was rather similar (20 -45 nM) . However, the association rate constant (k ϩj ) for PS-A binding was greater than 5-fold higher than for Et-A or SB-205952. This suggests some contribution of the side chain to initial binding. The differences between the compounds increased further at equilibrium (e.g. K j * was 20-fold lower for PS-A than Et-A). This was due to differences in the degree of tightening of binding in the K j Ͼ K j * transition (K* ϭ (K j /K j * ) ϳ10 3 for PS-A, cf. 10 2 for SB-205952), that was partly but not entirely accounted for by a reduction in the reverse rate constant from E * ⅐J, k Ϫj * . No single parameter therefore had a dominant effect in determining the differences in potency between the compounds studied.
It is of interest to attempt to consider the consequences of different inhibitor kinetic/thermodynamic parameters in the context of inhibition of IleRS within the bacterial cell. Estimates of the expression level of IleRS, either measured directly or through the PS-A binding capacity (21) suggest around 3,000 molecules per bacterial cell. Using an estimate of the volume of a single bacterial (E. coli cell) of 1 ϫ 10 Ϫ15 liter (40) , the intracellular concentration of IleRS can be estimated to be around 5 M, vastly above the values reported here for the dissociation constant for binding of any of the inhibitors. In the cellular context, therefore, tight-binding kinetics are likely to dominate and uptake of inhibitor into the bacterium is likely to be as important a process in governing antibacterial activity as the K j * . However, under these circumstances, the sequestering of inhibitor onto IleRS, thus keeping the intracellular inhibitor concentration close to zero and maintaining an inwardly directed concentration gradient is likely to be a major factor in uptake (21) .
Together, these experiments allowed a reasonably complete kinetic description of the inhibition of IleRS by a range compounds. Moreover, by analogy with the changes in IleRS tryptophan fluorescence that occur during the normal reaction cycle (see Ref. 12) , the experiments yielded intriguing insights into the likely conformation of the IleRS⅐inhibitor complexes. This data has already proved useful in the design of IleRS inhibitors which combine features from monic acid analogues with those from the more obvious reaction-intermediate analogues (e.g. Ile-ol-AMP) resulting in further increases in potency. 2 This work has been given extra impetus by the recent solution of the crystal structure of the complex between T. thermophilus IleRS and pseudomonic acid and experiments to further define those interactions between IleRS and inhibitors which play a significant role in selectivity (i.e. for bacterial IleRS) and the development of resistance are currently being investigated via further structural and site-directed mutagenesis approaches. The current work provides a coherent and detailed framework upon which to systematically analyze the consequences of such mutations.
